**Title:** Modified thromboelastography for peri-interventional assessment of platelet function in cardiology patients: a narrative review

**Short Title:** Platelet function testing using thromboelastography

**Authors:** Jan Hartmann, MD1, Nick Curzen, BM(Hons) PhD FRCP2

1 Haemonetics Corp., Boston, MA, United States

2 Faculty of Medicine, University of Southampton & Cardiothoracic Department, University Hospital Southampton, United Kingdom

**Corresponding Author**: Jan Hartmann, Chief Medical Officer, Haemonetics Corp, 125 Summer Street, Boston, MA 02110, United States.

Email: jan.hartmann@haemonetics.com

**References**: 86

**Figures and Tables**: 2

# **Abstract**

Viscoelastic testing (VET), such as thromboelastography, can measure whole blood coagulation dynamics in real time and is used across a range of clinical settings, including cardiac surgery, liver transplant, and trauma. The use of modified thromboelastography with platelet function assessment (TEG® PlateletMapping® Assay) can provide an analysis of platelet contribution to hemostasis, including the contribution of the P2Y12 receptor and thromboxane pathway to platelet function. The TEG® PlateletMapping® Assay has shown high correlation with the current gold standard test of platelet function, light transmission aggregometry, to measure AA and ADP agonist-induced platelet activation. Studies have also shown comparable results with other whole blood platelet function tests. In this review, we explore the clinical applications of modified thromboelastography with platelet function assessment. This includes guiding dual antiplatelet therapy in relation to cardiac procedures such as percutaneous coronary interventions, transcatheter aortic valve replacement and left atrial appendage closure. We also explore the developing use of thromboelastography in the emergency care setting of COVID-19, which is commonly associated with a hypercoagulable and hypofibrinolytic state. Despite a general lack of high-quality, grade 1 evidence regarding the use of modified thromboelastography with platelet function assessment in these disease areas, the ability of the TEG® PlateletMapping® Assay to measure global hemostasis and platelet reactivity rapidly and to view and evaluate results at the point of care makes it a promising area for further study for managing patient treatment and optimizing hemostatic therapy.

# **Introduction**

Thromboelastography, as with other forms of viscoelastic testing (VET), is a whole blood testing method in which clotting is observed in real time in an *in vitro* system that mimics physiological conditions.1-3 Thromboelastography has been widely used for patient management in clinical areas such as trauma,4, 5 cardiovascular surgery6, 7 and liver transplant surgery,8, 9 all of which share both hemorrhage and coagulopathy as common features.

Recently, there has been growing interest in the use of viscoelastic methods in the understanding and diagnosis of thrombotic conditions. In trauma, thromboelastography has been used to predict the development of pulmonary embolism (PE) following the acute stage.10 In the COVID-19 pandemic, viscoelastic parameters have been explored as a means to assess the risk for thromboembolic complications, such as venous thromboembolism (VTE).11-14 Most recently, modified thromboelastography with platelet function assessment has been studied for its predictive potential for complications, such as graft thrombosis and infection, following vascular surgery in patients with peripheral artery disease (PAD).15

Modified thromboelastography with platelet function assessment (TEG® PlateletMapping® Assay, Haemonetics Corp., Boston, MA, U.S.A.) provides specific additional functionality, given that standard thromboelastography is not able to precisely detect hemostatic changes introduced by platelet inhibiting agents. The specific design of assays for the arachidonic acid (AA) and adenosine diphosphate (ADP) pathways provide a measure of platelet reactivity via pathways (partially) blocked by aspirin and ADP receptor inhibitors (e.g., clopidogrel, ticagrelor), respectively.16 This introduces the concept of measuring both platelet reactivity and therapeutic responses to these agents.

The TEG® PlateletMapping® Assay is a whole blood platelet function test that is rapid, simple and can be viewed and evaluated at the point of care. This makes it particularly attractive for use in cardiovascular medicine, where randomized controlled trials of other platelet function tests (PFTs), such as the laboratory-based light transmission aggregometry (LTA), have repeatedly demonstrated large inter-individual response to antiplatelet agents.17-19 This wide variability of individual response has also been repeatedly demonstrated using TEG®5000 technology (Haemonetics Corp., Boston, MA, U.S.A.). Such variability inevitably raises concern that patients with relatively low response to antiplatelet drugs will be at increased risk of thrombotic/ischemic events, whereas patients with an exaggerated response could be at increased bleeding risk. This hypothesis has consistently been supported by a wide range of observational studies using a variety of platelet function assays, including TEG® assays, but randomized trials confirming a benefit to manipulating individual responses are not so far available.

Findings from a number of earlier randomized controlled trials using standard laboratory PFTs did not demonstrate clear clinical benefit of PFT-guided individualized anti-platelet therapy.20-22 It is perhaps notable that the latter trials all employed the VerifyNow™ assay to detect low response to clopidogrel, and concerns have been raised about the accuracy of this test in this context (see below). However, the recent TROPICAL-ACS RCT demonstrated a potential role for PFTs (Multiplate® analyzer, Roche Diagnostics, Indianapolis, IN, U.S.A.) to guide de-escalation of antiplatelet therapy and was included in a recent expert consensus statement,23 as well as the 2018 ESC/EACTS Guidelines on myocardial revascularization.24 Modified thromboelastography with platelet function assessment, in the form of the TEG®6s Analyzer, represents a convenient, whole blood methodology for testing individual response to antiplatelet medications that provides a more comprehensive overview of hemostasis.

We review the potential role of modified thromboelastography with platelet function assessment in the clinical setting of (a) peri-interventional cardiology, (b) for assessment of COVID-19 disease status and management.

# **The** **TEG® PlateletMapping® Assay**

Alongside the clotting dynamics measurements provided by the TEG® hemostasis analyzer, the TEG® PlateletMapping® Assay is able to provide a semi-quantitative analysis of platelet function through evaluation of the contribution of the ADP or Thromboxane A2 receptors. While standard viscoelastic testing uses an activator such as kaolin or tissue factor in a whole blood sample to accelerate the coagulation process, the TEG® PlateletMapping® Assay also adds ADP or AA agonists in order to assess platelet reactivity in response to these agonists. These responses can be assessed relative to (a) the standard kaolin-activated TEG® assay, which is taken as the maximal hemostatic activity and (b) the assay run with the addition of heparin, can be considered to correspond to the baseline platelet function. By adding the ADP and AA platelet activators into the sample with heparin, the contribution of ADP and TxA2 receptors to the formation of the clot can be measured (**Figure 1**).25, 26 These channels of measurement thus provide an assessment of the response to ADP and AA agonists relative to the maximum platelet-induced clot for that individual and, further, can be used to estimate their response to antiplatelet medication.

The next generation TEG®6s device uses resonance-frequency whole blood viscoelasticity to assess hemostasis during clot initialization, formation and lysis. As the whole blood sample coagulates to form a clot, the modulus of elasticity – and, therefore, the resonant frequency of the sample – increases. The variations in resonant frequency are measured by the analyzer and displayed as a TEG® assay trace. This system requires a much lower blood volume (~340microliter) for coagulation analysis compared with the previous generation TEG®5000 device, which uses a rotating cup and static pin to measure the sheer viscosity of the coagulating sample. Furthermore, the TEG®6s device uses a disposable four channel cartridge to process whole blood samples for assays, and this simplified assay procedure increases the ease of use and substantially reduces the time required for results compared with the TEG®5000 device.27, 28 The TEG®6s device has been assessed and validated for the assessment of coagulation dynamics in cardiology patients,29 trauma patients30 and in cardiothoracic surgery,31 showing high within-device reliability, good diagnostic accuracy and close correlation of results with the previous generation TEG®5000 device.32 With the TEG®6s device, the PlateletMapping® assay comes as a single cartridge, containing all necessary components to evaluate the activity of the AA and ADP pathways. This cartridge correlates well with the TEG®5000 PlateletMapping® assay in the detection of individual response to P2Y12 inhibitors.28

# **Comparison of the TEG® PlateletMapping® Assay with other PFTs**

The TEG® PlateletMapping® Assay has shown high correlation with LTA, the current gold standard platelet function test, when used to measure the ability of AA and ADP agonists to induce *in vitro* platelet-to-platelet activation.33 Correlation between the TEG® PlateletMapping® Assay and LTA has also been seen in clinical trials, such as the DIVIDE study (http://clinicaltrials.gov/show/NCT03062462), which used both assays to assess the response to P2Y12 receptor inhibitors in Chinese patients with acute coronary syndrome (ACS) in order to compare the antiplatelet action of half-dose ticagrelor and high-dose clopidogrel.34

Studies have also been carried out comparing TEG® PlateletMapping® Assay results against those of other whole blood PFTs, including VerifyNow™, Multiplate®, and PFA-100 assays. Comparison of three whole blood PFTs (TEG® PlateletMapping® Assay, VerifyNow™ platelet function testing system (Werfen, Bedford, MA, U.S.A.) and Multiplate®) for *in vitro* P2Y12 receptor-induced platelet inhibition showed the performance of the TEG® PlateletMapping® Assay to be similar – and in some respects superior – to the other assays, with the TEG® PlateletMapping® Assay showing lower variability vs. VerifyNow™ and Multiplate®.35 In contrast to VerifyNow™, the TEG® PlateletMapping® assay does not include prostaglandin E1 (PGE1) as an agonist for assessing the inhibition of the P2Y12 pathway. Data suggest that this provides a more accurate assessment of platelet aggregation in patients on clopidogrel compared with VerifyNow™.36, 37 As the TEG® PlateletMapping® Assay – in a similar manner to LTA – is able to directly indicate inhibition of cyclooxygenase, it is also likely to give a more accurate measure of high on treatment platelet reactivity (HTPR) with aspirin compared with nonspecific laboratory measurements, which are affected by other platelet activation pathways and can, therefore, overestimate HTPR with aspirin.38 This is with the caveat that previous data derived using the TEG® PlateletMapping® Assay in cardiology, acute stroke and vascular surgical patients suggested that AA-induced clotting is subject to intra-individual variability in patients on aspirin39-41 and that an inducible and/or recruitable cyclo-oxygenase independent pathway, not fully blocked by aspirin, probably accounts for the apparently high levels of HTPR with aspirin seen in such patient groups.42, 43

A large scale proficiency testing program carried out by the College of American Pathologists assessed data from over 1000 American laboratories from 2012–2016 for a number of platelet function test devices: PFA-100, LTA, PlateletWorks® (Helena Laboratories, Beaumont, TX, U.S.A.) and TEG®5000 analyzer with the PlateletMapping® Assay.44 The highest percentage of correct results compared with a standard reference was observed with PFA-100 and a much lower percentage with TEG®5000; although it has been noted45 that this did not take into account the context relating to the TEG® device as the only comprehensive, whole blood test included in the program that encompasses additional contributors to coagulation, such as platelet fibrin linkage. Additionally, given the relative complexity of the assays, there is likely to be higher operator variability in the TEG®5000 device used in this study compared with the TEG®6s analyzer. Other studies using the TEG®5000 PlateletMapping® Assay also show a range of correlations with whole blood PFTs, with no single platelet function assay consistently found to be preferable.46-48 Such comparisons inevitably raise fundamental questions as to how to define and use a “reference” with which to produce a measure of relative efficacy. Specifically, the longest established reference test could perform sub-optimally compared with a newer assay, but the assumption in traditional comparative pathways would assume the reverse was true.

# **Clinical Applications**

In the setting of cardiovascular disease management, there are a number of areas where knowledge of a patient’s platelet reactivity can be valuable. Platelet reactivity may be variable, and manipulated, at all stages of the patient treatment pathway: thus, there may be value in knowing individual reactivity at these stages when prescribing, or when trying to assess risk of bleeding or thrombotic events. For example, cardiac surgery is often associated with perioperative blood loss and a high risk of requiring allogenic blood transfusion.49 Secondly, it is well established that patients receiving drug-eluting coronary stents have a variable response to the antiplatelet drugs that they are prescribed, and that such individual responses are not routinely taken into account in our current “one size fits all” protocols. As a third example, consensus suggest that there is a need to identify COVID-19 positive patients (and possibly also some people receiving vaccinations) who are at highest risk of thrombotic complications. There are, therefore, several specific clinical applications in which platelet function testing has the potential to optimize and personalize therapy, thereby reducing patient risk.

## Percutaneous coronary interventions (PCI)

PCI is the commonest revascularization method for the treatment of obstructive coronary artery disease. An essential component of a successful intervention, especially involving stent implantation, is to inhibit platelet aggregation in order to avoid the development of ischemic complications. To this end, patients are treated with antiplatelet therapy both before and following the PCI procedure.50

Despite currently missing validated treatment alternatives, it is nevertheless remarkable that, despite the well documented inter-individual variation in response to aspirin and P2Y12 inhibitors, no assessment of patient response is routinely made in clinical practice. Furthermore, the prevailing agenda in the field of PCI practice is to minimize the bleeding risk for post stent patients by cutting down the time that patients are on dual antiplatelet therapy.51 Whilst most trials have dropped the P2Y12 inhibitor early and left the patient on aspirin alone, there have been studies stopping the aspirin early and retaining either clopidogrel alone or ticagrelor as the sole antiplatelet agent.52-54 Given the well documented prevalence of hypo-responsiveness to clopidogrel55 (and to a lesser extent both prasugrel and ticagrelor), and the historic association with ischemic complications, such strategies taken in the absence of any personalized measures of response are difficult to justify.

In reality, therefore, while it is not currently common practice to test for platelet function in patients undergoing PCI with stents, there remains a significant percentage of patients who experience adverse outcomes while receiving DAPT, either bleeding events due to low on-treatment platelet reactivity or thrombotic events due to hypo-responsiveness to antiplatelet therapy.56 There is therefore potential utility for assays for platelet reactivity to monitor the individual response to DAPT following PCI, in order to optimize effectiveness by identifying the ideal therapeutic window between the risks of bleeding and thrombosis (**Figure 2**).41, 57 For example, in the large randomized, controlled CREATIVE (Clopidogrel Response Evaluation and AnTi-platelet InterVEntion in High Thrombotic Risk PCI Patients, NCT01779401) trial, 1078 patients were stratified to standard or intensified antiplatelet therapies based on TEG® PlateletMapping® Assay results. For patients who showed low responsiveness to clopidogrel treatment, an intensified antiplatelet treatment regime significantly improved clinical outcomes with reduced rates of adverse cardiac and cerebrovascular events 18 months following PCI, without increasing the risk of major bleeding.58 There is an increasing amount of data from East Asia which suggests that patients have more HTPR with DAPT compared with European and American populations, potentially due to genetic factors such as the higher prevalence of CYP2C19 polymorphisms in this population.59 A literature review of studies published in East Asian centers revealed a body of data focused on the use of the TEG® PlateletMapping® Assay to escalate DAPT treatment and personalize post PCI antiplatelet therapy.60 This may be particularly pertinent given the recent evidence suggesting benefit from early single antiplatelet therapy using clopidogrel alone.53, 54

Whole blood PFTs may thus be used to potentially predict patient risk following cardiology interventions. Patients with high ADP-induced platelet aggregation, particularly those on intensive clopidogrel therapy, have been shown to be at higher risk for ischemic events following PCI,61 with TEG® hemostatic assays and other PFTs showing prognostic utility for predicting long-term ischemic events, including ischemic and bleeding events over 3 years.56 The ADP-induced platelet inhibition rate measured by the TEG® PlateletMapping® Assay has been shown to correlate with long-term outcomes. For example, in a study of 451 patients with ACS, patients who experienced ischemic events had significantly lower ADP-induced platelet inhibition compared with those that had no events (p<0.001), with 76% inhibition rate acting as a cut-off for prediction of rehospitalization for unstable angina within 1 year.62 Furthermore, multiple other studies have demonstrated an association between relative hypo-responsiveness to clopidogrel, or other P2Y12 inhibitors, and stent thrombosis.63-65 The evidence of a link between responsiveness to antiplatelet therapy and ischemic events, as well as the increasing use of more potent antiplatelet therapies, indicate that there may be a benefit of measuring individual response to P2Y12 inhibitors to modify therapy where appropriate.65 The availability of a simple, quick, accurate, reproducible platelet function test that can be viewed and evaluated at the point of care could render the concept of routine testing and tailored therapy for patients receiving coronary stents in order to optimize outcome highly plausible.

## TAVR

Transcatheter aortic valve replacement (TAVR) is a non-surgical treatment for aortic stenosis in which a replacement valve is fitted percutaneously, using large bore introducer sheaths most commonly via femoral or subclavian arteries, that is associated with bleeding complications.66 The risk of bleeding relates not just to the arterial access, but also to systemic anticoagulation during the procedure with unfractionated heparin, as well as pretreatment with antiplatelet medication (usually aspirin alone). There are no specific guidelines that address the use of hemostasis assays or PFTs during or after this procedure, and there is a paucity of evidence. However, viscoelastic testing has been reported to identify a prothrombotic signal during TAVR,67 with the interesting observation that TAVR is more prothrombotic than PCI, possibly because it is associated with greater endothelial damage and much more extensive vascular instrumentation as well as contact activation on the device.68 Using TEG® hemostasis assays to measure the strength of the fibrin clot immediately following the procedure has also been shown to be predictive of short-term major bleeding complications.69 Although the clinical implications remain uncertain, this indicates that further research should determine whether there is a role for the routine use of coagulation monitoring plus or minus platelet function assessment, e.g., with the TEG® PlateletMapping® Assay during this specific intervention.

Left atrial appendage closure

Left atrial appendage closure (LAAC) using the WATCHMAN™ device (Boston Scientific, Marlborough, MA, U.S.A.) is deployed for patients with non-valvular atrial fibrillation as an alternative to long-term anticoagulation therapy.70 The device has a high success rate, with a low incidence of adverse events. However, a small proportion of patients show device-related thrombus formation following the procedure.71 Detailed thrombogenicity phenotyping using thromboelastography together with biomarker assessment determined a baseline prothrombogenic profile associated with device-related thrombosis following LAAC in one prospective case-control study.72 Major bleeding following the procedure was also associated with low platelet reactivity. While the study did not assess the use of PFTs to measure platelet reactivity, this would be an interesting further area of research.

## Timing of Cardiac Surgery

Cardiac surgery can either be carried out as an urgent/emergency procedure, in the event of acute coronary syndromes, recurrent ischemia or acute valve presentations, or as elective surgery. Cardiac surgery is often associated with perioperative blood loss requiring allogenic blood transfusions.73 The use of TEG® technology is well established in clinical practice to assess hemostasis and platelet function throughout the surgical procedure. Algorithms that monitor platelet function alongside assessment of hemostasis during surgery have been shown to reduce bleeding and the requirement for allogenic blood transfusions.74 Prior to surgery, patients are required to stop some or all antiplatelet therapy whenever possible in order to reduce the likelihood of perioperative bleeding, with guidelines recommending waiting times of 5-7 days after stopping these medications.75 However, the use of a TEG® PlateletMapping® Assay-based management strategy to stratify patient waiting times based on platelet reactivity, was shown to reduce the waiting time after stopping antiplatelet medications (most commonly clopidogrel) to an average of 2.7 days, without increasing the bleeding risk or the use of blood products during surgery.76, 77 A similar study of patients in China, using the TEG® PlateletMapping® Assay to stratify pre-surgical timing for patients on DAPT, also reduced waiting time to 3.2 days prior to CABG, with no statistically significant difference in blood transfusions during surgery.67

## COVID-19

Coronavirus disease 19 (COVID-19) has been characterized as an infectious viral thromboinflammatory disease associated with dysfunction of hemostasis, most commonly a hypercoagulable and hypofibrinolytic state. Around 20% of COVID-19 patients rapidly progress to a severe illness that includes extensive thrombotic complications.78 Patients may experience both thrombotic and hemorrhagic symptoms, due to overactivation of platelets altering normal clotting, or to secondary inflammation resulting in decreased platelet count and low fibrinogen, usually as a result of consumption.12

If left untreated, the development of severe COVID-19 can involve serial iterations of thrombotic and bleeding or thrombocytopenic states, caused in large part by fluctuating levels of circulating inflammatory biomarkers.79 Depending on the severity and progression of the disease, patients can present with widely differing clinical profiles, which would likely be easier to manage if a full analysis of circulating biomarkers, clotting profile, and platelet function could be deployed in order to formulate a personalized, patient-specific approach.79 Typical laboratory hemostasis tests such as prothrombin time (PT) and activated partial thromboplastin time (aPTT) only analyze plasma and, therefore, cannot measure the contribution of platelets or fibrin to the clotting process. As clinical status can change in COVID-19 patients very swiftly, a rapid test that provides a comprehensive assessment of whole blood clotting and platelet reactivity and can be viewed and evaluated at the point of care could offer great potential for early detection and management of clotting abnormalities with the intention to prevent clinical deterioration.80 The TEG® 6s device represents a plausible candidate as such a test.

Studies using thromboelastography to monitor changing coagulation in patients with COVID-19 suggest that there is often a prognostic hypercoagulable profile with both an increased maximal amplitude and reduced fibrinolytic activity.12, 81 In children who develop multisystem inflammatory syndrome related to coronavirus, some observational and retrospective studies have shown unique TEG® assay profiles,82 with TEG® parameters correlating with disease severity and length of stay in intensive care.83 There are already some data to suggest that TEG® assay parameters may be used to predict thrombotic risk in COVID-19 patients with moderate or severe disease,84 and to identify the ideal therapeutic window for heparin treatment to prevent thrombosis without increasing the risk of bleeding.85

The use of whole blood PFTs, such as the TEG® PlateletMapping® Assay, adds an extra layer of information regarding the hemostatic status and response to treatment in patients with COVID-19. A study of 100 patients from a US tertiary care center indicated that the use of a treatment algorithm incorporating TEG® PlateletMapping® assessments was associated with a lower risk of requiring mechanical ventilation (relative risk = 10.9; p<0.0001), acute kidney injury (relative risk = 2.3; p=0.0017), kidney dialysis (relative risk = 7.8; p<0.0001), and death (relative risk = 7.7; p<0.0001) compared with patients not guided by the treatment algorithm.14 Specifically, platelet hyperactivity in patients with COVID-19, assessed by AA- and ADP- maximal amplitude, was associated with thrombotic or ischemic complications, while decreased platelet activity was associated with hemorrhagic complications.14 A study using the TEG® PlateletMapping® Assay in a largely African-American COVID-19 population identified a high proportion of patients with a suboptimal pharmacodynamic response to anticoagulants and aspirin, with patients on high dose aspirin still showing inadequate therapeutic response (50% of patients) and thromboinflammation (25% of patients).86

Due to the nature of COVID-19, and SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) as a relatively novel and infectious disease agent, there is a lack of high quality evidence from large scale clinical trials on the use of whole blood PTFs for diagnosis, and as part of treatment management. The currently ongoing TARGET-COVID study (NCT04493307) aims to evaluate hospitalized COVID-19 patients using a mix of thromboelastography, PFT, and biomarker analysis to determine individual patient thrombotic and bleeding risk to help personalize therapy and potentially improve clinical outcomes.84

# **Conclusion**

The facility for the TEG® PlateletMapping® Assay to assess global hemostasis and platelet reactivity in a rapid assay that can be viewed and evaluated at the point of care makes it a plausible potential candidate to be used routinely in several clinical settings in order to optimize patient care. Specifically, the failure to routinely assess the response of individuals receiving antiplatelet therapy in the context of drug-eluting stent PCI procedures is illogical, given the well described variability in individual responses to these agents, and the delicate balance between bleeding and ischemic events. Personalized, tailored antiplatelet therapy in such patients would be an attractive goal, and further research on the use of the TEG® device is warranted. The use of TEG® assays in TAVR patients to minimize bleeding complication rates also has intuitive appeal, just as the more widespread use in cardiac surgery may offer considerable clinical outcome and bed occupancy advantages. Finally, the characteristic COVID-associated pro-thrombotic and bleeding sequelae of the highly complex vascular inflammatory response that the infection induces may well be routinely tracked, with reactive therapeutic interventions in the future. Ongoing large-scale studies such as the RISTRATAVI ( Risk Stratification Post TAVI Using TEG, NCT03649594) trial on the use of TEG® assays to stratify risk following TAVI interventions, and the TARGET-COVID trial (NCT04493307) assessing the use of TEG® assays and PTFs in hospitalized COVID-19 patients, may help to answer some of the open questions regarding the clinical utility of the TEG® PlateletMapping® Assay.

# **Acknowledgements**

Editorial assistance was provided by Meridian HealthComms Ltd, funded by Haemonetics SA, Signy, Switzerland, in accordance with Good Publication Practice (GPP3).

# **Conflicts of Interest**

J.H is an employee of Haemonetics Corp.

N.C has received unrestricted research grants and consultancy fees from Haemonetics Corp.

# **References**

1.Hartmann J, Murphy M, Dias JD. Viscoelastic Hemostatic Assays: Moving from the Laboratory to the Site of Care-A Review of Established and Emerging Technologies. Diagnostics (Basel) 2020; 10(2)

2.Faraoni D, DiNardo JA. Viscoelastic hemostatic assays: Update on technology and clinical applications. Am J Hematol 2021; 96(10): 1331-7

3.Erdoes G, Koster A, Levy JH. Viscoelastic Coagulation Testing: Use and Current Limitations in Perioperative Decision-making. Anesthesiology 2021; 135(2): 342-9

4.Gonzalez E, Moore EE, Moore HB, et al. Goal-directed Hemostatic Resuscitation of Trauma-induced Coagulopathy: A Pragmatic Randomized Clinical Trial Comparing a Viscoelastic Assay to Conventional Coagulation Assays. Ann Surg 2016; 263(6): 1051-9

5.Baksaas-Aasen K, Gall LS, Stensballe J, et al. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. Intensive Care Med 2021; 47(1): 49-59

6.Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88(2): 312-9

7.Redfern RE, Fleming K, March RL, et al. Thrombelastography-Directed Transfusion in Cardiac Surgery: Impact on Postoperative Outcomes. Ann Thorac Surg 2019; 107(5): 1313-8

8.Kang YG, Martin DJ, Marquez J, et al. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 64(9): 888-96

9.Wang SC, Shieh JF, Chang KY, et al. Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial. Transplant Proc 2010; 42(7): 2590-3

10.Cotton BA, Minei KM, Radwan ZA, et al. Admission rapid thrombelastography predicts development of pulmonary embolism in trauma patients. J Trauma Acute Care Surg 2012; 72(6): 1470-5; discussion 5-7

11.Hartmann J, Ergang A, Mason D, et al. The Role of TEG Analysis in Patients with COVID-19-Associated Coagulopathy: A Systematic Review. Diagnostics (Basel) 2021; 11(2)

12.Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020; 18(7): 1738-42

13.Wright FL, Vogler TO, Moore EE, et al. Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection. J Am Coll Surg 2020; 231(2): 193-203.e1

14.Hranjec T, Estreicher M, Rogers B, et al. Integral Use of Thromboelastography With Platelet Mapping to Guide Appropriate Treatment, Avoid Complications, and Improve Survival of Patients With Coronavirus Disease 2019-Related Coagulopathy. Crit Care Explor 2020; 2(12): e0287

15.Majumdar M, Lella S, Hall RP, et al. Utilization of Thromboelastography with Platelet Mapping to Predict Infection and Poor Wound Healing in Postoperative Vascular Patients. Ann Vasc Surg DOI:https://doi.org/10.1016/j.avsg.2022.03.008

16.Preisman S, Kogan A, Itzkovsky K, et al. Modified thromboelastography evaluation of platelet dysfunction in patients undergoing coronary artery surgery. European Journal of Cardio-Thoracic Surgery 2010; 37(6): 1367-74

17.Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27(6): 647-54

18.Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 2012; 125(10): 1276-87; discussion 87

19.Gurbel PA, Bliden KP, Guyer K, et al. Platelet Reactivity in Patients and Recurrent Events Post-Stenting. Journal of the American College of Cardiology 2005; 46(10): 1820-6

20.Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 2016; 388(10055): 2015-22

21.Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. Jama 2011; 305(11): 1097-105

22.Collet JP, Cuisset T, Rangé G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367(22): 2100-9

23.Sibbing D, Aradi D, Alexopoulos D, et al. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y(12) Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC Cardiovasc Interv 2019; 12(16): 1521-37

24.Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal 2018; 40(2): 87-165

25.Bochsen L, Wiinberg B, Kjelgaard-Hansen M, et al. Evaluation of the TEG platelet mapping assay in blood donors. Thromb J 2007; 5: 3

26.Ranucci M, Baryshnikova E. Sensitivity of Viscoelastic Tests to Platelet Function. J Clin Med 2020; 9(1)

27.Dias JD, Lopez-Espina CG, Bliden K, et al. TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care. Platelets 2020; 31(7): 932-8

28.Olechowski B, Dalton RT, Khanna V, et al. Detection of individual responses to clopidogrel: Validation of a novel, rapid analysis using thrombelastography 6s. Cardiovasc Ther 2018; 36(4): e12433

29.Gurbel PA, Bliden KP, Tantry US, et al. First report of the point-of-care TEG: A technical validation study of the TEG-6S system. Platelets 2016; 27(7): 642-9

30.Neal MD, Moore EE, Walsh M, et al. A comparison between the TEG 6s and TEG 5000 analyzers to assess coagulation in trauma patients. J Trauma Acute Care Surg 2020; 88(2): 279-85

31.Erdoes G, Schloer H, Eberle B, et al. Next generation viscoelasticity assays in cardiothoracic surgery: Feasibility of the TEG6s system. PLoS One 2018; 13(12): e0209360

32.Lloyd-Donald P, Churilov L, Cheong B, et al. Assessing TEG6S reliability between devices and across multiple time points: A prospective thromboelastography validation study. Sci Rep 2020; 10(1): 7045

33.Craft RM, Chavez JJ, Bresee SJ, et al. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004; 143(5): 301-9

34.Liu GZ, Zhang S, Sun DH, et al. Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study). Eur J Clin Pharmacol 2019; 75(8): 1059-68

35.Dias JD, Pottgiesser T, Hartmann J, et al. Comparison of three common whole blood platelet function tests for in vitro P2Y12 induced platelet inhibition. J Thromb Thrombolysis 2020; 50(1): 135-43

36.Khanna V, Armstrong PC, Warner TD, et al. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography. Platelets 2015; 26(7): 689-92

37.Khanna V, Hobson A, Mikael R, et al. Does the VerifyNow P2Y12 assay overestimate "therapeutic response" to clopidogrel? Insights using short thrombelastography. Thromb Haemost 2014; 111(6): 1150-9

38.Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46(9): 1705-9

39.Khanna V, Mikael R, Thayalasamy K, et al. Does the response to aspirin and clopidogrel vary over 6 months in patients with ischemic heart disease? J Thromb Haemost 2015; 13(6): 920-30

40.Sambu N, Radhakrishnan A, Englyst N, et al. "Aspirin resistance" in ischemic stroke: insights using short thrombelastography. J Stroke Cerebrovasc Dis 2013; 22(8): 1412-9

41.Sambu N, Dent H, Englyst N, et al. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. Heart 2011; 97(20): 1661-7

42.Olechowski B, Ashby A, Mariathas M, et al. Is arachidonic acid stimulation really a test for the response to aspirin? Time to think again? Expert Rev Cardiovasc Ther 2017; 15(1): 35-46

43.Hobson AR, Qureshi Z, Banks P, et al. Effects of clopidogrel on "aspirin specific" pathways of platelet inhibition. Platelets 2009; 20(6): 386-90

44.Chandler WL, Brown AF, Chen D, et al. External Quality Assurance of Platelet Function Assays: Results of the College of American Pathologists Proficiency Testing Program. Arch Pathol Lab Med 2019; 143(4): 472-82

45.Hartmann J. External Quality Assurance of Platelet Function Assays: Results of the College of American Pathologists Proficiency Testing Program. Arch Pathol Lab Med 2019; 143(8): 914-6

46.Karon BS, Tolan NV, Koch CD, et al. Precision and reliability of 5 platelet function tests in healthy volunteers and donors on daily antiplatelet agent therapy. Clin Chem 2014; 60(12): 1524-31

47.Agarwal S, Coakley M, Reddy K, et al. Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry. Anesthesiology 2006; 105(4): 676-83

48.Blais N, Pharand C, Lordkipanidzé M, et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost 2009; 102(2): 404-11

49.Raphael J, Mazer CD, Subramani S, et al. Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. Anesth Analg 2019; 129(5): 1209-21

50.Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46(10): 1820-6

51.Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58(24): e44-122

52.Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 2018; 392(10151): 940-9

53.Hahn J-Y, Song YB, Oh J-H, et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA 2019; 321(24): 2428-37

54.Watanabe H, Domei T, Morimoto T, et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA 2019; 321(24): 2414-27

55.Sharma RK, Reddy HK, Singh VN, et al. Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag 2009; 5: 965-72

56.Gurbel PA, Bliden KP, Navickas IA, et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 2010; 160(2): 346-54

57.Sambu N, Radhakrishnan A, Dent H, et al. Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry. Heart 2012; 98(9): 706-11

58.Tang YD, Wang W, Yang M, et al. Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial. Circulation 2018; 137(21): 2231-45

59.Dean L. Clopidogrel Therapy and CYP2C19 Genotype. In Medical Genetics Summaries, Pratt, V.M., Scott, S.A., Pirmohamed, M., Esquivel, B., Kane, M.S., Kattman, B.L., Malheiro, A.J., . National Center for Biotechnology Information (US) Bethesda (MD) 2018

60.Xu O, Hartmann J, Yi-Da T, et al. The use of thromboelastography in percutaneous coronary intervention and acute coronary syndrome in East Asia: A systematic literature review. J Clin Med. 2022 Jul; 11(13): 3652.

61.Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49(6): 657-66

62.Zou Y, Wang Y, Wu Y, et al. Prediction of residual ischemic risk in ticagrelor-treated patients with acute coronary syndrome. Thromb J 2022; 20(1): 21

63.Cotton JM, Worrall AM, Hobson AR, et al. Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography? Cardiovasc Ther 2010; 28(3): 139-46

64.Hobson AR, Petley G, Morton G, et al. Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy. Thromb J 2008; 6: 1

65.Olechowski B, Ashby A, Sambu N, et al. Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography. Case Rep Med 2016; 2016: 2096181

66.Reardon MJ, Adams DH, Kleiman NS, et al. 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2015; 66(2): 113-21

67.Fanning J, Roberts S, Merza M, et al. Evaluation of latest viscoelastic coagulation assays in the transcatheter aortic valve implantation setting. Open Heart 2021; 8(1)

68.Fanning JP, Roberts S, Natani S, et al. Abstract 11978: Increased Early Prothrombotic Potential of Transcatheter Aortic Valve Implantation Compared With Percutaneous Coronary Intervention Identified With Viscoelastic Hemostatic Assessment of Coagulation. Circulation 2021; 144(Suppl\_1): A11978-A

69.Rymuza B, Zbroński K, Scisło P, et al. Thromboelastography for predicting bleeding in patients with aortic stenosis treated with transcatheter aortic valve implantation. Kardiol Pol 2018; 76(2): 418-25

70.Wintgens LIS, Maarse M, Swaans MJ, et al. The WATCHMAN left atrial appendage closure device for patients with atrial fibrillation: current status and future perspectives. Expert Rev Med Devices 2020; 17(7): 615-26

71.Kar S, Doshi SK, Sadhu A, et al. Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device: Results From the PINNACLE FLX Trial. Circulation 2021; 143(18): 1754-62

72.Sherwood M, Bliden KP, Ilkhanoff L, et al. Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study. J Thromb Thrombolysis 2020; 50(3): 484-98

73.Crawford TC, Magruder JT, Fraser C, et al. Less Is More: Results of a Statewide Analysis of the Impact of Blood Transfusion on Coronary Artery Bypass Grafting Outcomes. Ann Thorac Surg 2018; 105(1): 129-36

74.Karkouti K, Callum J, Wijeysundera DN, et al. Point-of-Care Hemostatic Testing in Cardiac Surgery: A Stepped-Wedge Clustered Randomized Controlled Trial. Circulation 2016; 134(16): 1152-62

75.Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non&#x2013;ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update). Circulation 2012; 126(7): 875-910

76.Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012; 5(2): 261-9

77.Yang Z, Xie Z, Pei X, et al. Effect of thrombelastography on timing of coronary artery bypass grafting. Exp Ther Med 2018; 16(2): 579-84

78.Laubscher GJ, Lourens PJ, Venter C, et al. TEG®, Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy. Journal of Clinical Medicine 2021; 10(22): 5381

79.Grobler C, Maphumulo SC, Grobbelaar LM, et al. Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes. Int J Mol Sci 2020; 21(14)

80.Laubscher GJ, Lourens PJ, Venter C, et al. TEG(®), Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy. J Clin Med 2021; 10(22)

81.Gurbel PA, Bliden KP, Levy JH, et al. Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm? Blood Coagul Fibrinolysis 2021; 32(8): 544-9

82.Ankola AA, Bradford VR, Newburger JW, et al. Coagulation profiles and viscoelastic testing in multisystem inflammatory syndrome in children. Pediatric Blood & Cancer 2021; 68(12): e29355

83.Morparia K, Spinella PC, McQueen D, et al. Thromboelastography profiles in critically ill children with multisystem inflammatory syndrome. Pediatric Blood & Cancer 2022; 69(5): e29426

84.Chaudhary R, Kreutz RP, Bliden KP, et al. Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry. Thromb Haemost 2020; 120(11): 1594-6

85.Stillson JE, Bunch CM, Gillespie L, et al. Thromboelastography-Guided Management of Anticoagulated COVID-19 Patients to Prevent Hemorrhage. Semin Thromb Hemost 2021; 47(4): 442-6

86.Gurbel PA, Bliden KP, Rout A, et al. Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population. J Thromb Thrombolysis 2021; 51(4): 902-4

# **Figures and Tables**

**Figure 1: Use of platelet receptor specific tracing to identify platelet inhibition and aggregation**

****

AA, arachidonic acid; ActF, activator F; ADP, adenosine diphosphate

**Figure 2: Use of platelet-function tests for guiding and personalizing antiplatelet therapy based on platelet responsiveness**



PFT, platelet function test